March 17 (Reuters) - Incyte INCY.O said on Monday its experimental drug has met the main goal in two separate late-stage studies testing it in patients with an inflammatory skin condition called hidradenitis suppurativa.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Shailesh Kuber)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.